Quipt Home Medical (NASDAQ:QIPT – Get Free Report) and Mangoceuticals (NASDAQ:MGRX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.
Valuation & Earnings
This table compares Quipt Home Medical and Mangoceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quipt Home Medical | $244.72 million | 0.45 | -$6.76 million | ($0.17) | -14.94 |
| Mangoceuticals | $730,000.00 | 14.77 | -$9.21 million | ($5.79) | -0.75 |
Quipt Home Medical has higher revenue and earnings than Mangoceuticals. Quipt Home Medical is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
Profitability
This table compares Quipt Home Medical and Mangoceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quipt Home Medical | -2.90% | -6.70% | -2.94% |
| Mangoceuticals | -1,237.00% | -138.00% | -118.88% |
Risk & Volatility
Quipt Home Medical has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Quipt Home Medical and Mangoceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quipt Home Medical | 1 | 0 | 3 | 2 | 3.00 |
| Mangoceuticals | 0 | 0 | 0 | 0 | 0.00 |
Quipt Home Medical presently has a consensus target price of $6.25, indicating a potential upside of 146.06%. Given Quipt Home Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Quipt Home Medical is more favorable than Mangoceuticals.
Summary
Quipt Home Medical beats Mangoceuticals on 10 of the 15 factors compared between the two stocks.
About Quipt Home Medical
Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Receive News & Ratings for Quipt Home Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quipt Home Medical and related companies with MarketBeat.com's FREE daily email newsletter.
